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Mast Cells Contribute to Scar Formation during
Fetal Wound Healing
Brian C. Wulff1, Allison E. Parent1, Melissa A. Meleski1, Luisa A. DiPietro2, Megan E. Schrementi2 and
Traci A. Wilgus1
Scar formation is a potentially detrimental process of tissue restoration in adults, affecting organ form and
function. During fetal development, cutaneous wounds heal without inflammation or scarring at early stages of
development; however, they begin to heal with significant inflammation and scarring as the skin becomes more
mature. One possible cell type that could regulate the change from scarless to fibrotic healing is the mast cell.
We show here that dermal mast cells in scarless wounds generated at embryonic day 15 (E15) are fewer in
number, less mature, and do not degranulate in response to wounding as effectively as mast cells of fibrotic
wounds made at embryonic day 18 (E18). Differences were also observed between cultured mast cells from E15
and E18 skin, with regard to degranulation and preformed cytokine levels. Injection of mast cell lysates into E15
wounds disrupted scarless healing, suggesting that mast cells interfere with scarless repair. Finally, wounds
produced at E18, which normally heal with a scar, healed with significantly smaller scars in mast cell-deficient
KitW/Wv mice compared with Kitþ /þ littermates. Together, these data suggest that mast cells enhance scar
formation, and that these cells may mediate the transition from scarless to fibrotic healing during fetal
development.
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INTRODUCTION
Wound healing is an important sequence of events following
tissue injury that can have detrimental outcomes, such as
fibrosis and scarring. Although our understanding of the
regulatory signals in adult wound healing and scar formation
have improved, scarring still cannot be completely prevented
in mature skin. Interestingly, scarless healing can occur in the
skin at early stages of fetal development in many mammals
(reviewed in Wilgus, 2007 and Larson et al., 2010).
Cutaneous wounds generated early in development have
very limited, if any, inflammation and heal scarlessly with
regeneration of dermal appendages like hair follicles. In
contrast, wounds generated late in fetal development have
robust inflammation and heal with a scar (fibrotic healing).
Previous studies have demonstrated that a limited inflamma-
tory response is essential for scarless repair (Krummel et al.,
1987; Frantz et al., 1993; Haynes et al., 1994; Liechty et al.,
1998, 2000; Martin et al., 2003; Wilgus et al., 2004). Many
aspects of the inflammatory phase in fetal wounds have been
studied; however, surprisingly little is known about the
response of mast cells to wounding at early stages of
development.
Resident mast cells are known to rapidly degranulate after
injury, releasing many pro-inflammatory and immunomodu-
latory proteins. Later in the healing process, mast cells
migrate to the site of injury, markedly increasing in number
(Trautmann et al., 2000). Mast cells are thought to be
important for wound healing by releasing many preformed
mediators after injury, and upon stimulation, they produce
even more mediators (reviewed in Hebda et al., 1993 and
Artuc et al., 1999). These molecules can influence important
aspects of healing, such as inflammation, angiogenesis, and
collagen production. Despite the growing understanding of
the role of mast cells in adult wound healing, their role in the
conversion from scarless to fibrotic healing has not been
examined. In this study, a mouse model of fetal repair in
which embryonic day 15 (E15) wounds heal scarlessly and
embryonic day 18 (E18) wounds heal with a scar (Wilgus
et al., 2004) is used to show that mast cells promote scarring
in fetal wounds.
RESULTS
Distinct features of resident mast cells in E15 and E18 fetal skin
To determine differences in mast cells before and after the
transition from scarless to fibrotic wound healing, mast cells
were examined in unwounded dorsal skin from E15 and E18
fetuses. Marked differences were observed in the number,
size, granularity, and maturity of mast cells. Toluidine blue
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staining showed that E15 skin contained less than half the
number of mast cells per mm2 as E18 skin (Figure 1a). Similar
numbers of tryptase-positive mast cells were observed by
immunohistochemistry, confirming reduced mast cell num-
bers in E15 skin (data not shown). Individual mast cells in E15
dermal tissue were significantly smaller in size (Figure 1b)
and less granular (Figure 1c) than those of E18 skin,
suggesting that the mast cells in E15 skin may be less mature.
Alcian blue–safranin staining was then used as an indicator of
mast cell maturity (Figure 2). Normal E15 and E18 fetal skin
had similar percentages of mast cells at an intermediate stage
of maturity (mixture of blue and red granules); however, there
were strong differences in the percentage of mature (red
granules) and immature (blue granules) mast cells. In E15
fetal skin, 54% of the mast cells were immature and only 6%
of the mast cells were mature. Conversely, in E18 fetal skin,
only 1% of the mast cells were immature, and 56% of the
mast cells were of a mature phenotype.
Age-dependent differences in mast cells after injury
Next, changes in mast cell number and activation in response
to wounding were examined. Fetal skin was harvested at
times ranging from 2 to 72 hours post wounding and stained
with toluidine blue. The number of fully granulated mast cells
decreased significantly in the dermis adjacent to wounds in
E18 fetal skin at all time points after wounding compared
with unwounded E18 skin. A decrease in mast cell density is
commonly seen in adult wounds with toluidine blue staining
and is attributed to the degranulation of mast cells (el Sayed
and Dyson, 1993). In contrast to E18 wounds, the number of
mast cells in E15 wounds is initially stable over time and
eventually increases after several days (Figure 3a). This would
be expected based on the increase in mast cell density seen
as fetal skin develops (Figure 1a).
After mast cells degranulate, granule remnants can often
be observed in the tissue (Kovanen, 1993). These granule
remnants adjacent to the wound edge were counted to
quantify degranulation (Figure 3b). Very few granule rem-
nants were observed in E15 wounds at any time point,
suggesting that mast cells were not activated in response to
injury (Figure 3c). However, in E18 skin, the number of
granule remnants in the dermis increased at early time points
post wounding, indicating strong mast cell activation/
degranulation (Figure 3d). This corresponded to the decrease
in toluidine blue-stained mast cells seen in E18 skin
(Figure 3a). Together, the differences in mast cell character-
istics in unwounded skin and mast cell degranulation after
injury support the hypothesis that mast cells contribute to the
transition from scarless to fibrotic wound healing.
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Figure 1. Characterization of mast cells in unwounded fetal skin.(a) Mast cell
density, (b) size, and (c) granularity, as estimated by staining intensity, were
determined in toluidine blue-stained sections of unwounded embryonic day
15 (E15) ( ) or embryonic day 18 (E18) (’) fetal skin. Bars represent the
mean±SEM (n¼ 9 E15 and n¼ 6 E18 skin samples; **Po0.01, ***Po0.001).
Representative photomicrographs of toluidine blue-stained (d) E15 and
(e) E18 fetal skin are shown. Bars¼ 50 mm and dotted lines mark the
dermal–epidermal junction. Higher magnification photomicrographs show
a representative mast cell from (f) E15 and (g) E18 skin. Bars¼ 10 mm.
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Figure 2. Analysis of mast cell maturity in fetal skin.Mast cells in embryonic
day 15 (E15) or embryonic day 18 (E18) skin were categorized as immature,
intermediate, or mature based on staining with alcian blue–safranin.
Representative photomicrographs of (a) E15 and (b) E18 skin are shown.
Bars¼ 20 mm and dotted lines mark the dermal–epidermal junction. Cells with
granules that stained blue were considered immature (’), cells with granules
that stained red were considered mature (&), and cells with red and blue
granule staining were considered intermediate ( ). Arrows indicate
representative mast cells from each category. The percentages of cells at each
level of maturity are shown in c. Bars represent mean±SEM (n¼ 8 E15 and
n¼ 6 E18 skin samples; **Po0.01, ***Po0.001).
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Phenotypic differences in cultured fetal mast cells
To further understand developmental changes in mast cells,
in vitro experiments were performed using cultured mast cells
from E15 skin (E15MC) and E18 skin (E18MC). Similar to
what was seen in vivo (Figure 2), staining with alcian
blue–safranin showed that E15MC had an immature pheno-
type (blue granules; Figure 4a), compared with E18MC (red or
red and blue granules; Figure 4b). Tryptase b-1 was present in
both E15MC and E18MC by western blot (Figure 4c), and no
significant differences in protein levels were detected by
densitometry (Figure 4d). Histamine levels were higher in
E18MC compared with E15MC, but this difference was not
statistically significant (Figure 4e). However, tumor necrosis
factor (TNF)-a (Figure 4f) and vascular endothelial growth
factor (VEGF; Figure 4g) levels were both higher in E18MC
compared with E15MC. Responsiveness of the mast cells to
C48/80 was determined by quantification of b-hexosamini-
dase and histamine release. Both b-hexosaminidase and
histamine release were significantly higher in E18MC
compared with E15MC (Figure 4h and i), suggesting that
E18MC are more sensitive to degranulation stimuli than
E15MC. These in vitro findings support the differences seen
in vivo demonstrating a more mature and responsive
phenotype in E18 mast cells.
Mast cell lysates disrupt scarless healing
To determine whether preformed mast cell mediators affect
scarless fetal healing, E15MC or E18MC lysates were injected
into E15 wounds, which normally heal without a scar.
Examination of trichrome-stained tissue sections showed that
scarless healing had occurred in all phosphate-buffered
saline-injected control wounds at 10 days post wounding
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Figure 3. Comparison of mast cell degranulation after wounding.The density
of (a) mast cells and (b) granule remnants were determined in the dermis
adjacent to wounds in embryonic day 15 (E15) ( ) or embryonic
day 18 (E18) (’) fetal skin using toluidine blue-stained sections. Values for
unwounded control skin (Ctrl) are included for reference. Bars represent
the mean±SEM (n¼3–9 fetuses per group; *Po0.05, ***Po0.001).
Representative photomicrographs of toluidine blue-stained
(c) E15 and (d) E18 skin harvested at 5 hours post wounding are shown.
Bars¼ 50 mm and dotted lines mark the dermal–epidermal junction.
Arrows indicate mast cells ( ) and granule remnants ( ).
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Figure 4. Differences in cultured mast cells from E15 skin (E15MC) and E18
skin (E18MC).Cells from embryonic day 15 (E15) or embryonic day 18
(E18) skin were cultured for 14 days, and mast cells were purified by
centrifugation in 40% Percoll. Representative alcian blue–safranin-stained
cytospins of (a) E15MC and (b) E18MC are shown. Bars¼ 20mm. (c) Tryptase
b-1 was detected by western blot and (d) the density of tryptase b-1/b-actin
was determined. (e) Histamine, (f) tumor necrosis factor (TNF)-a, and
(g) vascular endothelial growth factor (VEGF) content in cell lysates were
determined by ELISA. TNF-a was not detected (n.d.) in E15MC samples.
Values were normalized to total protein (mg). Degranulation in response to
C48/80 at various doses was determined by (h) b-hexosaminidase (b-hex) and
(i) histamine release. Bars represent the mean±SEM (n¼ 3–8 per group from
separate cultures; *Po0.05, **Po0.01, ***Po0.001).
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(Figure 5a). Both lysate preparations disrupted scarless
healing (Figure 5b and c); however, only 26% (5/19) of
wounds injected with E15MC lysate healed with a scar
compared with 53% (19/36) of wounds injected with E18MC
lysate. In addition, scars from wounds injected with
E15MC lysate were 2/3 the width of those injected with
E18MC lysate, although this difference was not statistically
significant (Figure 5d). These results suggest that mast cell
mediators augment scar formation.
Reduced scarring in mast cell-deficient fetuses
To assess whether the absence of mast cells would reduce
scar formation, mast cell-deficient (KitW/W-v) and wild-type
(Kitþ /þ ) fetuses were wounded at E18, and harvested at 7 or
10 days post wounding (Figure 6a–d). Significant differences
in scar width were observed in trichrome-stained sections
(Figure 6e), with less scar tissue produced in the absence of
mast cells. No differences were detected in the density of
collagen types I and III or in collagen organization within the
scars using immunohistochemistry and picrosirius red stain-
ing (data not shown). Together with the results in Figure 5,
these data provide strong evidence that mast cells contribute
to the production of scar tissue in fetal wounds.
DISCUSSION
Evidence has been mounting in support of a role for mast
cells in various phases of wound healing in adult skin,
especially during the inflammatory phase. In contrast to
mature skin, early embryonic wounds lack a pronounced
inflammatory phase, and heal quickly and scarlessly (Colwell
et al., 2003; Wilgus, 2007; Hantash et al., 2008; Larson et al.,
2010). At later stages of development, fetal skin heals
similarly to adult skin. Although many studies have shown
that a vigorous inflammatory response is coincidental with
fibrotic healing in late gestation fetal wounds, it is still not
clear what is responsible for the onset of inflammation and
subsequent scarring in this model. Surprisingly, despite the
known importance of resident mast cells in the initiation of
acute inflammation and their suggested link to fibrosis, the
role of mast cells in fetal wound healing has not been
assessed.
The present study compared mast cells at different stages
of development and examined the function of these cells
in scar formation using a mouse model of fetal wound
healing. There were striking differences in resident mast cell
90
70
80
60
50
40
30
20
10
0
E15 MC
lysate
E18 MC
lysate
Sc
ar
 w
id
th
 (μ
m
)
Figure 5. Effects of mast cell lysate injection on scarless healing.Wounds
were generated on embryonic day 15 (E15) and injected with (a) phosphate-
buffered saline or lysate from cultured mast cells from (b) E15 skin (E15MC) or
(c) E18 skin (E18MC). Samples were harvested at 10 days post wounding.
Representative photomicrographs of trichrome-stained wound sections are
shown. Bars¼ 100mm, and arrows denote the wound/scar margins. The width
of the scars was measured and the data are shown in d. Bars represent
mean±SEM (n¼ 5 E15MC scars and n¼ 19 E18MC scars).
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Figure 6. Analysis of scar formation in mast cell-deficient fetuses.
KitW/W-v and Kitþ /þ littermates were wounded at embryonic day 18 (E18),
and wounds were harvested (a, b) 7 or (c, d) 10 days post wounding.
Representative photomicrographs of trichrome-stained scars from (a, c) mast
cell-deficient KitW/W-v mice and (b, d) normal Kitþ /þ littermates are shown.
The scar margins are marked by arrows. Bars¼ 200 mm. (e) Trichrome-stained
sections were used to determine the size of the scars. Bars represent the mean
scar width±SEM (n¼5–11 wounds per group; *Po0.05, **Po0.01).
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populations in the skin at times that correspond with scarless
(E15) and fibrotic (E18) repair. Unwounded E18 skin
contained approximately twice the number of mast cells
compared with E15 skin, and the mast cells present in E18
skin were larger, more granular, and more mature. These
results are similar to other published studies indicating an
increase in mast cell number and maturity during embryonic
development (Combs et al., 1965; Savall and Ferrer, 1981;
Kasugai et al., 1993). When the mast cell response to injury
was examined, mast cell degranulation was not observed in
E15 wounds. In contrast, a pattern of mast cell degranulation
similar to what has been reported for adult skin wounds
(el Sayed and Dyson, 1993) was seen in E18 wounds.
Interestingly, cultured E15MC were also less mature and
less responsive to C48/80, a commonly used activator of
degranulation, compared with E18MC. The increased capa-
city of mast cells in E18 skin to degranulate could be because
of the fact that the cells are more mature, and thus more
responsive to stimuli than mast cells from E15 skin. It is also
likely that signals stimulating mast cell degranulation may
only be present in the skin at later stages of development. The
marked increase in mast cell number, maturity, and activa-
tion in E18 skin suggests a possible role for mast cells in the
conversion from scarless to fibrotic healing in the fetus.
To further explore the role of mast cells in the switch to
fibrotic healing, experiments were designed to test the effects
of mast cells on scarless repair. In these studies, a single
injection of lysate from either E15MC or E18MC into E15
wounds disrupted scarless healing, suggesting that mediators
derived from mast cells augment scar formation in fetal
wounds. Although the exact mediator or combination of
mediators responsible is not known, many molecules stored
in mast cell granules could be contributing to scar formation.
Several studies have indicated that mast cell proteases have
fibrogenic effects. Tryptase has been shown to have
chemotactic and mitogenic effects on dermal fibroblasts,
and it also stimulates procollagen mRNA synthesis, contrac-
tion, and differentiation into myofibroblasts (Gruber et al.,
1997; Gailit et al., 2001; Albrecht et al., 2005). Chymase can
cleave procollagen type I, which allows for collagen fibril
formation (Kofford et al., 1997). Other mast cell mediators
such as histamine can also increase collagen production in
fibroblasts (Hatamochi et al., 1985; Kupietzky and Levi-
Schaffer, 1996; Gailit et al., 2001). In addition, VEGF and
IL-6, which are stored in mast cells, have been shown to
promote scar formation in early-gestation fetal wounds
(Liechty et al., 2000; Wilgus et al., 2008). Interestingly,
cultured E15MC and E18MC retained some of the features of
mast cells in E15 and E18 fetal skin. E15MC were less mature
by alcian blue–safranin staining and contained significantly
less TNF-a and VEGF than E18MC. E15MCs were also less
responsive to C48/80. Despite these differences, both lysates
had some effect when injected into E15 wounds. However, a
higher percentage of the wounds injected with E18MC lysate
healed with a frank scar, and the size of the scars were 1/3
larger compared with wounds injected with E15MC lysate.
Interestingly, both E15MC and E18MC contained tryptase,
which could explain why the E15MC lysate also disrupted
scarless healing to some extent. It should be noted that
fetal skin would not likely encounter the mediators present
within E15MC under normal circumstances, because as
shown here, E15 mast cells do not degranulate in response
to injury. In any case, these data show that exposure of fetal
wounds to mast cell mediators can interfere with scarless
repair.
In addition to artificially exposing E15 wounds to mast cell
mediators, mast cell-deficient KitW/W-v mice were used to
assess the contribution of mast cells to scar formation in E18
wounds. Mast cell-deficient KitW/W-v fetuses healed with
significantly smaller scars compared with wild-type Kitþ /þ
mice. Although there was less scarring in KitW/W-v mice, these
wounds did not heal completely without a scar, suggesting
that mast cells have a part in scar formation, but are not the
only factor involved. For example, inherent differences in
early-gestation dermal fibroblasts are thought to direct
scarless healing (Lorenz et al., 1995), and differences in the
behavior of early and late gestation fibroblasts have been
described (Sandulache et al., 2007; Hirt-Burri et al., 2008;
Brink et al., 2009; Carter et al., 2009). Therefore, it is possible
that even in the absence of mast cells, E18 KitW/W-v fetuses
cannot achieve completely scarless healing, because the
fibroblasts have already lost the ability to mediate scarless
repair at this late stage in development.
Several mast cell-deficient strains exist (Kitamura et al.,
2001; Grimbaldeston et al., 2005); however, the KitW/W-v
mice are the most commonly used strain and have been used
to study adult wound healing. Using the Kitw/w-v strain, mast
cells have been shown to impact neutrophil infiltration,
suggesting that mast cells are heavily involved in the
regulation of acute wound inflammation (Egozi et al., 2003;
Weller et al., 2006). Another study suggested a role of mast
cells in collagen remodeling (Iba et al., 2004), but to date, a
comprehensive study examining scar formation in KitW/W-v
mice has not been published. In addition to lacking mast
cells, the KitW/W-v mice have defects in melanogenesis, are
sterile, and develop macrocytic anemia. Although we do not
believe these issues contributed significantly to the results
seen in the fetal wound model described here, we cannot
completely rule out this possibility. Other mast cell-deficient
mouse models were considered for these experiments, but it
has been reported that dermal mast cells are present in
developing skin in these alternative strains, with the skin only
becoming significantly mast cell deficient after birth (Kita-
mura and Go, 1979; Yamazaki et al., 1994; Kitamura et al.,
2001). For this reason, the KitW/W-v strain was the most
suitable for these studies.
Although the studies presented here are the first to
describe a role for mast cells in scar formation in fetal
wounds, previous studies have suggested that mast cells are
involved in clinically significant abnormal scarring. Keloids
and hypertrophic scars both contain high numbers of mast
cells (Hakanson et al., 1969; Kischer et al., 1978; Smith et al.,
1987; Boyadjiev et al., 1995; Harunari et al., 2006), and
recently, the mast cell stabilizer ketotifen was shown to
reduce contraction and scar tissue deposition in a hyper-
trophic scar model (Gallant-Behm et al., 2008). Mast cells are
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also thought to contribute significantly to fibrotic diseases in
the skin and other organs, such as scleroderma and
pulmonary fibrosis (Atkins and Clark, 1987; Gruber, 2003).
Overall, the data presented here provide further evidence that
mast cells could be a viable target for anti-fibrosis and anti-
scarring therapies.
MATERIALS AND METHODS
Animals
Mice were handled in accordance with the Ohio State University
Institutional Animal Care and Use Committee guidelines. FVB mice
(Taconic Farms, Hudson, NY) or male C57BL/6J-KitW-v/J and female
WB/Rej KitW/J mice (Jackson Laboratories, Bar Harbor, ME) were
time-mated, and detection of a vaginal plug was designated E0.
Because mast cell-deficient KitW/W-v mice are sterile, heterozygous
WB/Rej Kitw/J females were mated with C57BL/6J-KitW-v/J males to
generate mast cell-deficient WBB6F1-KitW/W-v (KitW/W-v) fetuses and
normal WBB6F1-Kitþ /þ (Kitþ /þ ) littermates. Mast cell-deficiency in
KitW/W-v skin was confirmed by toluidine blue staining (data not
shown). FVB mice were used in all studies unless otherwise
indicated.
Full-thickness dorsal fetal wounds were generated at E15 or E18,
as described (Wilgus et al., 2008). After wounding, 1ml of
phosphate-buffered saline or mast cell lysate (described below)
containing 10% India ink was injected subcutaneously at the wound
site. Wounded animals were euthanized at various time points post
surgery. Skin from age-matched unwounded animals served as
controls. Samples were fixed in 10% formalin overnight and
embedded in paraffin for histology.
Mast cell culture
Mast cells were isolated using published methods with slight
modifications. E15 or E18 skin was digested by incubation in
complete RPMI 1640 containing 1.5mgml1 collagenase and
0.5mgml1 hyaluronidase at 37 1C for 1 hour (Sigma Aldrich, St
Louis, MO; Benyon et al., 1987). Cells were strained through a nylon
strainer, and red blood cells were lysed with ACK buffer (Invitrogen,
Carlsbad, CA). Cells were then cultured for 14 days as described
(Yamada et al., 2003) in RPMI 1640-containing IL-3 and stem cell
factor (10 ngml1 each; Peprotec, Rock Hill, NJ). Mast cells were
purified using 40% isotonic Percoll (Yamada et al., 2003). Cells were
used for cytospin preparations or resuspended at a concentration of
4 106 mast cells per ml in phosphate-buffered saline and lysed via
sonication (three rounds of ten 1-s pulses). Lysates were centrifuged
to remove cellular debris, and aliquots were stored at 80 1C until
use. Lysates were prepared for injection by diluting with phosphate-
buffered saline and India ink (10%) to a concentration equivalent to
900 lysed mast cells per ml. This preparation (1 ml) was injected into
fetal wounds as described above.
Protein analysis
For protein analysis, cultured mast cells were lysed by sonication in
RIPA buffer-containing protease inhibitor cocktail (Thermo Scien-
tific, Rockford, IL). After centrifugation, total protein concentrations
were determined using the bicinchoninic acid protein assay (Thermo
Scientific).
Tryptase b-1 and b-actin levels were determined by western blot
using standard methods. Total protein (5 mg) was separated on 12%
SDS-polyacrylamide gels, and transferred onto polyvinylidene
difluoride membranes (Bio-Rad Laboratories, Hercules, CA). Mem-
branes were blocked and probed for mouse tryptase b-1 (R&D
Systems, Minneapolis, MN). Membranes were stripped with Restore
PLUS buffer (Thermo), blocked, and probed for b-actin (Cell
Signaling Technology, Danvers, MA). Proteins were visualized using
Immun-Star WesternC chemiluminescence reagents, and digital
images were captured using the Chemidoc XRS imaging
system (Bio-Rad). Densitometry was performed using Quantity
One software (Bio-Rad), and data are presented as density of
tryptase b-1/b-actin.
Histamine, TNF-a, and VEGF content was measured using
commercially available kits according to manufacturer’s instruc-
tions. For each sample, 5 ng (histamine EIA; Oxford Biomedical
Research, Oxford, MI) or 50 mg (TNF-a and VEGF ELISA; R&D
Systems) of total protein was used for the assays.
Degranulation assays
Degranulation of cultured mast cells was assesed by measuring b-
hexosaminidase and histamine release. b-Hex assays were per-
formed as described previously (Ortega et al., 1989). A 20 ml volume
containing 2 104 cultured mast cells and C48/80 at final
concentrations ranging from 0 to 100mgml1 in Tyrode’s buffer
were used for each reaction. For histamine release, 10-fold dilutions
of supernatant and lysed pellet from the b-hexosaminidase assay
were analyzed using a histamine EIA (Oxford Biomedical Research).
The percent release was calculated using the following formula:
((amount in supernatant)/(amount in supernatantþ amount in
pellet)) 100.
Histochemical stains
Toluidine blue, which stains mast cell granules blue (Smith and
Atkinson, 1956), was used to identify dermal mast cells by staining
paraffin sections with 0.2% toluidine blue (Sigma Aldrich) in 0.7 N
HCl overnight. Mast cells were counted under light microscopy
using an Axioscope 40 microscope (Carl Ziess, Thornwood, NY) in
five high-power fields per sample of unwounded dorsal skin. Digital
pictures were then taken using an AxioCam MRc 5 digital camera
(Carl Ziess). Ten individual mast cells per sample were traced and
the mean area and the integrated density of staining, as a
measurement of granularity, were calculated for each mast cell.
For wounds, mast cell numbers and extracellular granule remnants
(Lindstedt et al., 2001) were counted in two fields of skin
immediately adjacent to either side of the wound (total of four
fields). To control for differences in dermal thickness between E15
and E18 skin, the area of the dermis for each field was determined
using Axiovision software (Carl Zeiss). Mast cell or granule remnant
densities (numbers per mm2) were then calculated.
Alcian blue–safranin was used to distinguish between immature
and mature mast cells by staining paraffin sections or acetone-fixed
cytospin preparations as described (Csaba, 1969; Kalesnikoff and
Galli, 2011). Mast cells were categorized as immature if the granules
stained blue, mature if the granules stained red, or intermediate if
they contained a mixture of blue and red granules (Combs et al.,
1965).
Masson’s trichrome staining was used to visualize scar tissue as
described (Wilgus et al., 2003, 2008), and scar widths were
measured using Axiovision software (Carl Zeiss).
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Statistics
Prism (Graphpad, La Jolla, CA) was used for statistical analysis.
Student’s two-tailed t-test or two-factor analysis of variance with
Bonferroni’s post-hoc tests were used. P values o0.05 were
considered statistically significant.
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